BioMAP℠ Webinar Series
BioMAP® - solutions for phenotypic drug discovery
In this webinar series, we showcase how to apply the unique BioMAP platform of predictive human-based models to the discovery and development of safer and more efficacious therapeutics and chemicals. BioMAP profiles provide actionable data to guide lead selection, lead optimization (SAR), mechanistic understanding of compound action, and nomination of candidates for preclinical development. Topics covered include general technology overview as well as focused topics covering introduction and overview, data analysis, oncology, safety and toxicology and more.
Webinars will continue to be added to this series, so please check back often.
Loading...
| Event Date ▼ |
Event Name |
PDF Link |
Webinar Link |
| April 19, 2017 |
Webinar: Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing - 40 min.
What will be covered?
- Using phenotypic profiling to characterize clinically successful drugs for a given indication
- Combining target-based and phenotypic data to prioritize drugs for repurposing
- Understanding how multi-targeted kinases can be pivoted towards new indications
|
|
|
| October 26, 2016 |
Webinar: Target to Phenotype: Tools to Accelerate Your Immuno-Oncology Drug Pipeline - 60 min.
What will be covered?
- Challenges in immuno-oncology drug development
- Tools to expedite and simplify any immuno-oncology drug development pipeline
|
|
|
| September 30, 2016 |
Webinar: Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models - 60 min.
What will be covered?
- Overview of the BioMAP® immuno-oncology/oncology systems
- Information BioMAP iOnc studies provide
- Host stromal/vascular - tumor microenvironment biology
- Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds
|
|
|
| August 10, 2016 |
Webinar: New Tricks for Old Drugs: An Unbiased Phenotypic Approach to Drug Repurposing - 40 min.
What will be covered?
- Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
- Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
- Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications
|
|
|